Revolutionary Drug Discovery Platform
A new way of drugging with small molecules
Interdict Bio develops small molecules called Interdictors™ that interrupt (interdict) the supply of pathogenic proteins to cells by inhibiting protein synthesis by the ribosome in a context-dependent manner. We are focused on validated yet historically undruggable targets in oncology, neurodegeneration and beyond.
What are Interdictors™?
Interdictors™ are orally bioavailable small molecule drugs that inhibit protein synthesis by the ribosome in a context-dependent manner by interacting with the nascent polypeptide. Our proprietary platform enables generation of Interdictors™ targeting historically undruggable targets in oncology, neurodegenerative diseases, and more.
Explore our science
Our pipeline
Our lead program to address the previously ‘undruggable’ oncogenic transcription factor MYC is in IND-enabling studies for MYC-dependent cancers. Additional internal programs focus on other targets key to hematological and solid tumor cancers, as well as neurodegenerative diseases.
See our pipeline
Our team
Our multi-disciplinary team includes deep expertise in medicinal chemistry, clinical and computational sciences, structural biology, ribosome biology, cancer biology, and neuroscience. Alongside our scientific team, our advisory board and founders are committed to advance the novel Interdictor™ modality and provide breakthrough treatments for patients across therapeutic areas.
Meet the team
